Neuropathy Therapies Tested in 2026: Red Light, Capsaicin, Exercise and 4 More (and What Is Still Hype)

Search for neuropathy relief online and you will meet red-light boots, stem cell clinics, magnetic gadgets and “nerve regeneration” creams, many of them sold with a glowing before-and-after story. Some of these approaches have real trials behind them. Others have almost none. In 2026, new studies on several of them were published, and the gap between marketing and evidence is easy to see once you read the originals.

This page lists seven non-pill approaches that were studied this year, in order of how close each is to helping you. For every item we give the date, where it was published, whether it was tested in people or animals, and whether you can get it today. It is a companion to our list of new neuropathy drugs and procedures and to our guide to diabetic neuropathy, where most of these studies took place.

1. Strengthening Exercise Ranked Best for Diabetic Nerve Pain in a 2026 Review

Status: available now, with your doctor’s okay. Published October 2026 in Pain Management Nursing. Pooled results of trials in people.

A network meta-analysis compared exercise types for pain from diabetic peripheral neuropathy. It pooled 18 randomized trials with 1,121 patients, found through a search completed in April 2025. Multi-component exercise programs significantly reduced pain, and whole-body vibration exercise also showed pain-relieving effects. When the exercise types were ranked, strengthening exercises came first, followed by whole-body vibration. The authors recommend both as core strategies.

The abstract does not report how much pain fell or for how long, and exercise trials are hard to blind, so treat the ranking as a direction, not a prescription.

What it means for you: light strength work is cheap, safe for most people and already part of the routine in our guide to exercises for neuropathy. Start gently, check your feet for blisters afterward, and ask your doctor before trying a vibration platform, especially if you have foot sores or severe numbness.

2. The Capsaicin 8% Patch Improved Sensation Over a Year in a Follow-Up Analysis

Status: available now by prescription, applied in a clinic. Published June 2026 in Muscle & Nerve. Tested in people.

The high-concentration capsaicin patch (Qutenza) has been FDA-approved since July 2020 for nerve pain from diabetic neuropathy of the feet. A new post hoc analysis of the PACE study looked at feeling in the feet after repeated 30-minute treatments added to standard care. Among 156 treated patients, 21.1%, 26.4% and 22.8% moved from below-normal to normal sensation on heat, cold and sharp tests at month 12. In a second comparison, 88 treated patients with sensory loss at the start improved more than 89 patients on standard care alone on heat, sharp and vibration tests and on a diabetic neuropathy quality-of-life score.

Two caveats matter. A post hoc analysis looks at questions that were not the original goal of the study, so it can only suggest an effect, and the comparison was against standard care, not a placebo patch. The authors themselves say the findings need confirmation in dedicated trials. The study’s main analysis found that the patch did not worsen nerve function over 52 weeks.

What it means for you: this is the one item on the list that is both approved and getting better evidence. It is applied by a clinician, not at home, and it is not the same as the over-the-counter creams, which are a fraction of the strength. Our guide to home treatment for neuropathy in the feet explains the difference.

3. Red Light and Laser Therapy: One Device Beat Sham, One Pilot Did Not

Status: one prescription device studied; online red-light products are unproven. Published in Pain Research and Management (2026) and Lasers in Medical Science (July 10, 2026). Tested in people.

The stronger study was a double-blind, sham-controlled trial at four U.S. clinical sites with 64 adults with painful diabetic neuropathy. The device was a prescription home-use laser giving red (640 nm) and violet (405 nm) light, used for 5 minutes per foot twice a day for 3 weeks. At week 3, 72.7% of the real-device group had at least a 30% drop in foot pain versus 32.3% of the sham group. Average pain scores fell by 33.4 points versus 20.0 points. The benefit lasted through week 7 and there were no serious device-related side effects.

Look at the sham numbers: nearly a third of people using a fake device also improved, which is why a sham group matters. The study ended four weeks after treatment, so it shows short-term relief only, and the authors position the laser as an add-on to standard care.

The second study was a small pilot of 26 people split into local photobiomodulation (a form of red light therapy), the same plus intravascular laser irradiation of the blood (ILIB), and a sham group, over 12 sessions. Pain fell over time, but the authors found no clear difference between real and sham treatment and warn of placebo effects and the small size.

What it means for you: the positive trial tested a specific prescription device. It tells you nothing about the red-light boots, mats and wraps sold online, which differ in wavelength, power and design and were not studied here. If you are curious, ask a pain specialist whether a clinically tested device is available to you.

4. Magnetic Brain Stimulation Reduced Nerve Pain in a 2026 Meta-Analysis

Status: only in specialist clinics. Published June 2026 in Pain Practice. Pooled results of trials in people.

Repetitive transcranial magnetic stimulation (rTMS) uses a magnetic coil held against the scalp to stimulate brain areas involved in pain, without surgery. A meta-analysis of 9 sham-controlled trials with 435 people with peripheral neuropathic pain found that rTMS significantly reduced pain intensity. The chance of reaching a 30% pain reduction was about three times higher, but that result sat right at the edge of statistical significance. Sleep quality and the patients’ overall impression of change did not improve significantly, and side effects such as headache were not significantly more common.

The authors note high variation between trials and little long-term data. The studies covered peripheral neuropathic pain in general, not only diabetic neuropathy.

What it means for you: it is a clinic-based option, not something to buy. If medications have failed, it is a reasonable question for a pain or neurology specialist, who can tell you whether it is offered near you and what a course involves.

5. Moxibustion Combinations Looked Helpful in a 40-Trial Review, With a Safety Catch

Status: possible in traditional Chinese medicine clinics; ask about burn risk first. Published 2026 in Frontiers in Endocrinology. Pooled results of trials in people.

Moxibustion is a traditional Chinese medicine method that burns dried mugwort near the skin. A network meta-analysis searched trials through April 14, 2026 and pooled 40 randomized trials with 3,718 people with diabetic neuropathy. Moderate-certainty evidence favored moxibustion combined with external herbal medicine over conventional treatment alone for nerve conduction speed and for a clinical symptom score. Moxibustion with acupuncture also helped on one nerve test. The authors conclude that combinations may be a useful add-on, but that the findings require confirmation in rigorous trials.

The certainty of some results was rated very low, and the benefit came from combinations, not from moxibustion alone.

What it means for you: heat is the problem. Numb feet can miss a burn, and the U.S. National Institute of Diabetes and Digestive and Kidney Diseases advises against putting heating pads or hot water bottles on your feet. We would not try it unless a practitioner experienced with neuropathy checks the heat method with your doctor first. Our foot-care guide lists the NIH advice.

6. A Skin Cream Grew Nerve Fibres in a Phase 2a Trial, but Symptoms Did Not Clearly Improve

Status: not available; larger trials needed. Published January 2026 in EBioMedicine. Tested in rats and in people.

Pirenzepine is a drug that blocks one type of acetylcholine receptor, and in diabetic rats a topical version protected nerves. In the human trial, 58 adults with type 2 diabetic neuropathy at five Canadian university centres applied either placebo or a 4% pirenzepine solution to the skin for 24 weeks. Skin biopsies at the ankle showed nerve fibre density rose by 2.32 in the higher-dose group and 1.50 in the lower-dose group, while it fell by 0.71 on placebo.

That is a lab measurement, not a symptom. The quality-of-life improvement of 10.4 points appeared only in one analysis (per protocol) and disappeared in the main modified intention-to-treat analysis, which the authors flag as a reason for caution. Skin reactions at the application site were more common with the drug: 41.7% in the higher-dose group versus 8.3% on placebo. The funders listed include the Canadian Institutes of Health Research, Research Manitoba and WinSanTor.

What it means for you: nothing yet. It is a signal that nerve regrowth may be possible, and the authors say Phase 2b and Phase 3 trials are needed. Be skeptical of any cream sold today as “regenerating” nerves.

7. Stem Cells and Exosomes Are Still Lab Stage, and the FDA Is Warning Clinics

Status: lab stage; not FDA-approved for neuropathy. Reviews published March 5, 2026 (International Journal of Molecular Sciences) and October 6, 2026 (Molecular Neurobiology). Mostly tested in animals.

The March review covered 25 preclinical studies of mesenchymal stem cells for neuropathic pain, and 23 of them reported less pain in animals. The October review of stem cell exosomes (tiny particles released by cells) found 17 studies, 16 of them in animals and one a small pilot in people. Its authors write that “human evidence remains insufficient to establish clinical efficacy” and that randomized trials are required.

Meanwhile the FDA states that the only stem cell products it has approved are blood-forming stem cells for blood disorders, and that there are no FDA-approved exosome products. On August 14, 2026, it issued a warning letter to a company marketing umbilical cord and exosome products, noting that its website claimed they could reduce pain from conditions including neuropathy. The FDA called the products unapproved new drugs.

What it means for you: an injection sold for neuropathy at a private clinic is an unproven treatment, however confident the sales pitch. If you are interested in the science, look for a registered clinical trial instead, and ask any clinic for the FDA approval or trial number before paying.

How Can You Read a Therapy Claim Before You Pay for It?

The gap between the red-light trial and the red-light boots is a good example of why the details matter. Four questions separate a result from an advertisement:

1. Was there a sham or placebo group? In the laser trial, 32.3% of the sham group improved. Without that comparison, a result like “72.7% improved” would look far more impressive than it is.
2. How many people, and for how long? Twenty-six people over 23 days and 64 people over three weeks are early signals, not proof. Strengthening exercise and the capsaicin patch have longer records.
3. What was measured? Nerve fibre density in a biopsy, nerve conduction speed and your daily pain are three different things. A therapy can change the first two without helping the third.
4. Was it the exact product being sold? A prescription laser tested in four clinics does not validate every device with a red light bulb.

You can also look up any treatment on ClinicalTrials.gov, the free U.S. government registry. If it is being tested in people, it is listed there with its status.

What Should You Do With This News Now?

Two items are practical today: gentle strength work, with your doctor’s okay, and a conversation about the capsaicin patch if pain persists. The rest range from interesting to cautionary. As always, finding and treating the cause comes first, including keeping blood sugar steady and correcting confirmed deficiencies such as low vitamin B12. If your neuropathy came from cancer treatment, see our separate list of chemo neuropathy news in 2026.

Frequently Asked Questions